Skip to main content

Advertisement

SpringerLink
Log in

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

  • Gynecologic Cancers (LA Cantrell, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The choice of the right treatment regimen for recurrent ovarian cancer (rOC) remains a case-by-case decision. It is based on multiple factors that involve patient characteristics and biological factors at the same time. The prioritization of factors is still subject to changes with a trend towards a more personalized medicine. Therefore, participation and engagement in clinical studies constitutes a substantial need for the future development of the treatment algorithm of rOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.

    Article  Google Scholar 

  2. Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012;51(4):441–53.

    Article  Google Scholar 

  3. Group JALFARCFAG-MNCCSobotEGW. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;24(suppl_6):vi24–32.

    Google Scholar 

  4. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.

    Article  CAS  Google Scholar 

  5. Oskay-Ozcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, et al. Expression III: patients’ expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol. 2018;29(4):910–6.

    Article  CAS  Google Scholar 

  6. Irena Rohr MK, Chekerov R, Oskay-Özcelik G, Richter R, Heinrich M, Taskiran C, et al. What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. J Clin Oncol. 2017;35(15_suppl):e17096-e.

    Article  Google Scholar 

  7. Hack TF, Pickles T, Ruether JD, Weir L, Bultz BD, Mackey J, et al. Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psycho-oncology. 2010;19(6):606–16.

    Article  Google Scholar 

  8. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.

    Article  Google Scholar 

  9. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(2):289–95.

    Article  Google Scholar 

  10. • Andreas Du Bois IV, Gwenael Ferron, Alexander Reuss, Werner Meier, Stefano Greggi, Pernille Tina Jensen, Frédéric Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, , Elisabeth Avall-Lundqvist, Jae Weon Kim, Jordi Ponce, Francesco Raspagliesi, Sadaf Ghaem-Maghami, , Alexander Reinthaller, Philipp Harter, Jalid Sehouli. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35(15_suppl):5501. A randomized phase III study showing a PFS benefit of SSC in patients with first rOC only when CTR was achieved. OS data is not available yet.

    Article  Google Scholar 

  11. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–39.

    Article  Google Scholar 

  12. •• Wilson MK, Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S. J., Ferrero, A. M., Edmondson, R. J., Wimberger, P., , Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., Ochiai, K. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017;28(4):727–732. A consensus statement replacing the historical definition of platinum-free interval by therapy-free interval.

    Article  CAS  Google Scholar 

  13. Grabowsk JP, Martinez-Villa C, Richter R, Taube ET, Braicu EI, Sehouli J. Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer. J Clin Oncol. 2019;37(15_suppl):5577.

    Article  Google Scholar 

  14. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (London, England). 2003;361(9375):2099–106.

    Article  CAS  Google Scholar 

  15. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(29):4699–707.

    Article  CAS  Google Scholar 

  16. Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, et al. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). Int J Clin Oncol. 2019.

  17. Grabowski JP, Sehouli J. Current management of ovarian cancer. Minerva Med. 2015;106:151–6.

    CAS  PubMed  Google Scholar 

  18. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(33):5165–71.

    Article  CAS  Google Scholar 

  19. Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(9):1247–58.

    Article  CAS  Google Scholar 

  20. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.

    Article  CAS  Google Scholar 

  21. Perren TJ, Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., , Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stahle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K., Oza, A. M. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484–2496.

    Article  CAS  Google Scholar 

  22. Oza AM, , Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A, Park-Simon, T. W., Rustin, G., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A., Jayson, G. C., Stark, D., Swart, A. M., Farrelly, L., Kaplan, R, Parmar, M. K., Perren, T. J. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.

    Article  CAS  Google Scholar 

  23. agency Em. Avastin: EPAR- Product information Annex I https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf2018 [updated 31.08.201805.03.2019].

  24. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.

    Article  CAS  Google Scholar 

  25. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2039–45.

    Article  CAS  Google Scholar 

  26. • APD JP, Baumann K, Rau J, Harter P, Joly F, Sehouli J, et al. Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. Ann Oncol. 2018;29(Suppl 8):viii332–viii58 A randomized phase III study showing a significant improvement of PFS for treatment with CD-BEV compared to CG-BEV in patients with rOC suitable for platinum- based treatment.

    Google Scholar 

  27. Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol. 2018;36(15_suppl):5506.

    Article  Google Scholar 

  28. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1302–8.

    Article  CAS  Google Scholar 

  29. FDA. Full prescribing information for Lynparza https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf2018 [23.05.2019].

  30. FDA. Full prescribing information for Zejula https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf2017 [23.05.2019].

  31. FDA. prescribing information for rubraca https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf2018 [23.05.2019].

  32. EMA. Product information https://www.ema.europa.eu/en/documents/product-information/rubraca-epar-product-information_en.pdf2018 [cited 23.05.2019].

  33. EMA. product information https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf2018 [23.05.2019].

  34. EMA. Product information zejula https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_de.pdf2018 [cited 23.05.2019].

  35. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.

    Article  CAS  Google Scholar 

  36. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.

    Article  CAS  Google Scholar 

  37. Grabowski JP, Sehouli J, Glajzer J, Worm M, Zuberbier T, Maurer M, et al. Olaparib desensitization in a patient with recurrent peritoneal cancer. N Engl J Med. 2018;379(22):2176–7.

    Article  Google Scholar 

  38. • Pujade-Lauraine ELJ, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84 A double-blind, randomized, placebo-controlled, phase 3 trial showing a PFS benefit in patients with platinum- sensitive rOC and BRCAm when treated with olaparib.

    Article  CAS  Google Scholar 

  39. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018.

  40. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016(375):2154–64 A randomized, double-blind, phase 3 trial showing a PFS benefit in patients with platinum- sensitive rOC regardless of BRCA and HRD status when treated with niraparib.

  41. Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019:Jco1802238.

  42. Moore KN, Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., Cristea, M., Berek, J. S., , Chan, J. K., Rimel, B. J., Matei, D. E., Li, Y., Sun, K., Luptakova, K., Matulonis, U. A., Monk, B. J. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636–648.

    Article  CAS  Google Scholar 

  43. Konstantinopoulos PA, Waggoner SE, Vidal GA, Mita MM, Fleming GF, Holloway RW, et al. TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—results from ROC cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(suppl):106.

    Article  Google Scholar 

  44. Penson RT, Drew Y, de Jonge MJA, Hong S, Park YH, Wolfer A, et al. MEDIOLA: a phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours–new ovarian cancer cohorts. Ann Oncol. 2018;29(suppl_8):viii133–viii14.

    Google Scholar 

  45. Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, et al. Major clinical research advances in gynecologic cancer in 2018. J Gynecol Oncol. 2019;30(2):e18.

    Article  Google Scholar 

  46. Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23(15):4095–106.

    Article  CAS  Google Scholar 

  47. Swisher EMLK, Oza AM. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.

    Article  CAS  Google Scholar 

  48. Konecny GE, Oza AM, Tinkerc AV, Colemand RL, O'Malleye DM, Maloneyf L, et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecol Oncol. 2017;145(2):220.

    Google Scholar 

  49. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;390(10106):1949–61.

    Article  CAS  Google Scholar 

  50. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15–28.

    Article  CAS  Google Scholar 

  51. Berek JS, Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., , Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M. R. Safety and dose modification for patients receiving niraparib. Ann Oncol 2018;29(8):1784–1792.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Center of Oncological Surgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

    Joanna Glajzer LL.B, MD , Jacek P. Grabowski MD & Jalid Sehouli MD

  2. Gynecologic Oncology Center, Kiel, Germany

    Jacobus Pfisterer MD

Authors
  1. Joanna Glajzer LL.B, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacek P. Grabowski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jalid Sehouli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacobus Pfisterer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joanna Glajzer LL.B, MD .

Ethics declarations

Conflict of Interest

Joanna Glajzer declares that she has no conflict of interest.

Jacek P. Grabowski declares that he has no conflict of interest.

Jalid Sehouli declares that he has no conflict of interest.

Jacobus Pfisterer has received research funding (paid to his institution) from Roche Pharma AG and Tesaro; has received honoraria from Roche Pharma AG, AstraZeneca, Tesaro, Amgen, Clovis Oncology, and MSD Oncology; has received compensation from Roche Pharma AG, AstraZeneca, Tesaro, Clovis Oncology, and MSD Oncology for service as a consultant; and has received reimbursement for travel expenses from Roche Pharma AG and Tesaro.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Gynecologic Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Glajzer, J., Grabowski, J.P., Sehouli, J. et al. Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. Curr. Treat. Options in Oncol. 21, 49 (2020). https://doi.org/10.1007/s11864-020-00747-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00747-7

Keywords

Search

Navigation